FTO Promotes Osteosarcoma Progression via YAP and Reduces Cisplatin Sensitivity
Frontiers in Bioscience-Landmark · 15.10.2026 · 31 (10)
DOI: 10.31083/fbl53084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 15.10.2026. Verfasst von Zhaoliang Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, 710004 Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Osteosarcoma, Cisplatin, Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Bone Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research Project of Shaanxi Province.
Abstract (Originalsprache)
Background
Fat mass and obesity-associated protein (FTO), a key demethylase involved in N6-methyladenosine modification, plays significant regulatory roles in various cancers. However, its influence on osteosarcoma progression, sensitivity to the commonly used chemotherapy agent cisplatin, and downstream regulatory mechanisms remain unclear.
Methods
Multiple osteosarcoma cell lines were used for expression and drug-sensitivity screening, with MG-63 selected for mechanistic experiments. Genetically modified cell lines were established via viral infection and transfection. In vitro assays, including CCK-8, colony formation, Transwell, wound healing, and flow cytometry, were used to assess cell proliferation, migration, and cisplatin sensitivity. Subcutaneous xenograft and tail vein injection metastasis models were used to evaluate in vivo tumor growth and metastasis. Transcriptome sequencing was performed to identify downstream target genes.
Results
Compared to normal osteoblasts, FTO expression was elevated in osteosarcoma cell lines (p < 0.05). Knockdown of FTO inhibited osteosarcoma cell proliferation and migration, reduced tumor growth and metastasis in vivo, and increased sensitivity to cisplatin (all p < 0.01). In contrast, overexpression of FTO produced the opposite effects (all p < 0.05). Yes-associated protein (YAP) was identified as a downstream target of FTO. Overexpression of YAP rescued the tumor-suppressive effects caused by FTO knockdown (all p < 0.01), whereas YAP knockdown attenuated the tumor-promoting functions of FTO overexpression (all p < 0.05).
Conclusions
FTO is overexpressed in osteosarcoma, where it promotes tumor progression and reduces cisplatin sensitivity. YAP, as a downstream target of FTO, mediates the oncogenic functions of FTO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, 710004 Xi'an, Shaanxi, China.
- Medical College, Xijing University, 710123 Xi'an, Shaanxi, China.
Förderung
- Key Research Project of Shaanxi Province
Zitieren
APA
Shen, Z., Li, F., Chen, Z., Zhang, Y., Dang, X., & Wang, H. (2026). FTO Promotes Osteosarcoma Progression via YAP and Reduces Cisplatin Sensitivity. Frontiers in Bioscience-Landmark, 31(10). https://doi.org/10.31083/fbl53084
Vancouver
Shen Z, Li F, Chen Z, Zhang Y, Dang X, Wang H. FTO Promotes Osteosarcoma Progression via YAP and Reduces Cisplatin Sensitivity. Frontiers in Bioscience-Landmark. 2026;31(10). doi:10.31083/fbl53084
BibTeX
@article{Shen2026,
author = {Shen, Zhaoliang and Li, Fei and Chen, Zhihao and Zhang, Yuxing and Dang, Xiaoqian and Wang, Haoyu},
title = {FTO Promotes Osteosarcoma Progression via YAP and Reduces Cisplatin Sensitivity},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {10},
doi = {10.31083/fbl53084}
}
EUVIMED